US Domestic, Global Economic Outlook - Equity Research on DaVita Inc. and NxStage Medical, Inc.
October 04 2011 - 9:00AM
Marketwired
Today, www.EquityMarketsInc.com announced its research report
highlighting DaVita Inc. (NYSE: DVA) and NxStage Medical, Inc.
(NASDAQ: NXTM). Full content and research is available at
www.EquityMarketsInc.com/research.php?id=DVA+NXTM.
Short-term outlooks within US and global economies continue to
adjust downward, as US Treasury yields touched their lowest levels
in over 65 years. International Monetary Fund downgraded estimates
for US growth by 1.0% this year, down from 2.5%. 'Significant
downside risks' to the US economy were confirmed by the Federal
Reserve pressured by 'strains in global financial markets.'
As the US dollar trades above an eight-month high against the
Euro, it highlights a deepening of the Eurozone sovereign debt
crisis -- furthered by continued policy inaction from European
governments. We expect continued volatility until economic data
stabilizes and we see decisive policy action to deal with the
Eurozone debt crisis.
Our members are preparing for a turn in tides. Currently, the
Credit Suisse Risk Appetite Indicator is at a 30-year low. For the
past three occurrences, this level has acted as a leading indicator
of large stock market rallies 18 months following.
Equity Markets has reviewed DaVita Inc. for its current position
within the healthcare industry. DaVita Inc. is a provider of
dialysis services in the United States for patients suffering from
chronic kidney failure, which is an end stage renal disease (ESRD).
It provides hospital inpatient hemodialysis services, excluding
physician services, to patients in approximately 750 hospitals. The
full research report on DaVita Inc. (NYSE: DVA) is available here:
www.EquityMarketsInc.com/research.php?id=DVA.
Equity Markets has reviewed NxStage Medical, Inc. for its
development within the healthcare industry. NxStage Medical, Inc.
(NxStage) is a medical device company that develops, manufactures
and markets products for the treatment of kidney failure, fluid
overload and related blood treatments and procedures. Its primary
product includes the NxStage System One (the System One). NxStage
operates in two segments: System One and In-Center. The full
research report on NxStage Medical, Inc. (NASDAQ: NXTM) is
available here: www.EquityMarketsInc.com/research.php?id=NXTM.
About Equity Markets Our mission at Equity Markets is to be the
best source of content and research, while educating, enlightening
and informing investors. Equity Markets combines street smart
analysts and professional market researchers to provide investors
with detailed company profiles and market coverage.
Contact: Samuel Littman Email Contact
www.EquityMarketsInc.com
DaVita (NYSE:DVA)
Historical Stock Chart
From Oct 2024 to Nov 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Nov 2023 to Nov 2024